{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:46Z","timestamp":1790192806519,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cancer-associated thrombotic microangiopathy (TMA) is a rare disease, with a poor prognosis. The classical treatment is urgent chemotherapy. Few data are available on the efficacy of plasma exchange (PE) and eculizumab in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases of cancer-related TMA treated between January 2008 and December 2019 in 12 French treatment centres were retrospectively analysed, excluding cases associated with chemotherapy and stem cell transplantation. Patients were divided into four groups depending on the treatment received: none, PE therapy alone, chemotherapy, with or without PE therapy, or eculizumab, with or without chemotherapy and PE therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The data of 59 patients with cancer-associated TMA were analysed. Twenty of these cases were related to a cancer recurrence. The cancer was metastatic in 90% of cases (53\/59). Bone marrow invasion was observed in 20\/41 biopsies. Some laboratory results, including disseminated intravascular coagulation high ferritin and C-reactive protein, were suggestive of cancer. None of the 16 patients whose alternative complement pathway was assessed had abnormal levels of protein expression or activity. The median survival time was 27 days. Chemotherapy was significantly associated with improved survival, with a 30-day survival rate of 85% (17\/20) among patients who received PE and chemotherapy, versus 20% (3\/15) among patients who received PE alone. Patients treated with eculizumab in addition to chemotherapy and PE therapy did not have longer overall survival or higher haematological remission rates than those treated with chemotherapy and PE therapy alone. Renal remission rates were non-significantly higher, and times to remission non-significantly shorter, in the eculizumab group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nephrologists and oncologists should make themselves aware of cancer diagnoses in patients with TMA and bone marrow biopsies should be performed systematically in these cases. All 59 patients had poor survival outcomes, but patients treated with urgent initiation of chemotherapy survived significantly longer than those who were not.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ndt\/gfac213","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T06:27:03Z","timestamp":1657088823000},"page":"913-921","source":"Crossref","is-referenced-by-count":12,"title":["Retrospective study of 59 cases of cancer-associated thrombotic microangiopathy: presentation and treatment characteristics"],"prefix":"10.1093","volume":"38","author":[{"given":"Antoine","family":"Decaestecker","sequence":"first","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalier de Valenciennes , Valenciennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-206X","authenticated-orcid":false,"given":"Aghil\u00e8s","family":"Hamroun","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalo-Universitaire de Lille , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Provot","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalo-Universitaire de Lille , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[{"name":"Service d'Urgences N\u00e9phrologiques et Transplantation R\u00e9nale, H\u00f4pital Tenon, Assistance Publique des H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de N\u00e9phrologie et Transplantation d'organes, H\u00f4pital Rangueil, Intensive Care Unit, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Sallee","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation R\u00e9nale, H\u00f4pital de la Conception, Centre Hospitalo-Universitaire de Marseille , Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2514-4193","authenticated-orcid":false,"given":"Dimitri","family":"Titeca-Beauport","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation r\u00e9nale, Centre Hospitalo-Universitaire d'Amiens , Amiens , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Rebibou","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalo-Universitaire de Dijon , Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Forestier","sequence":"additional","affiliation":[{"name":"Centre Oscar Lambret, Service d'Oncologie , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Azar","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Dialyse, Centre Hospitalier de Dunkerque , Dunkerque , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Deltombe","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Immunologie clinique, Hotel Dieu, Centre Hospitalo-Universitaire de Nantes , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Wynckel","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation R\u00e9nale, Centre Hospitalo-Universitaire de Reims , Reims , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grange","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Tansplantation r\u00e9nale, Centre Hospitalo-Universitaire de Rouen , Rouen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Fremeaux Bacchi","sequence":"additional","affiliation":[{"name":"Laboratoire d'Immunologie biologique, HEGP H\u00f4pital Europ\u00e9en Georges Pompidou, Centre Hospitalo-Universitaire Paris Ouest , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cartery","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, Centre Hospitalier de Valenciennes , Valenciennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nephro.2017.01.023","article-title":"[Thrombotic microangiopathy and cancer]","volume":"13","author":"Kheder El-Fekih","year":"2017","journal-title":"Nephrol Ther"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.1970.tb01433.x","article-title":"Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma","volume":"18","author":"Brain","year":"1970","journal-title":"Br J Haematol"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.prp.2010.05.002","article-title":"Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature","volume":"206","author":"Chinen","year":"2010","journal-title":"Pathol Res Pract"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.8-4-375","article-title":"Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist"},{"key":"2023033113280995400_","first-page":"536","article-title":"[Microscopic tumor embolisms in metastasized breast carcinoma]","volume":"141","author":"van de Ven","year":"1997","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.21873\/anticanres.14393","article-title":"Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature","volume":"40","author":"Burns","year":"2020","journal-title":"Anticancer Res"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000338664","article-title":"KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury","volume":"82","author":"Mizuno","year":"2012","journal-title":"Oncology"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.reaurg.2008.03.014","article-title":"Approche critique des crit\u00e8res diagnostiques de coagulation intravasculaire diss\u00e9min\u00e9e","volume":"17","author":"Lerolle","year":"2008","journal-title":"R\u00e9animation"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.ejim.2015.09.007","article-title":"Hypervitaminemia B12 in elderly patients: frequency and nature of the associated or linked conditions. Preliminary results of a study in 190 patients","volume":"26","author":"Zulfiqar","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/qjmed\/hct051","article-title":"The pathophysiology of elevated vitamin B12 in clinical practice","volume":"106","author":"Andr\u00e8s","year":"2013","journal-title":"QJM"},{"key":"2023033113280995400_","first-page":"2244","article-title":"Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies","volume":"59","author":"Oleksowicz","year":"1999","journal-title":"Cancer Res"},{"key":"2023033113280995400_","first-page":"454","article-title":"Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: what is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am J Hematol"},{"key":"2023033113280995400_","article-title":"Pathophysiology of tumour-induced microangiopathic haemolytic anaemia","volume":"2016","author":"Chalasani","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1744-9987.2009.00710.x","article-title":"Fulminant plasmapheresis-refractory thrombotic microangiopathy associated with advanced gastric cancer","volume":"14","author":"Vasko","year":"2010","journal-title":"Therap Apher Dial"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1537-2995.2006.00687.x","article-title":"Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"46","author":"Howard","year":"2006","journal-title":"Transfusion (Paris)"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol"},{"key":"2023033113280995400_","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12907","article-title":"Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?","volume":"166","author":"Favre","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac213\/45192686\/gfac213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/4\/913\/49715386\/gfac213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/4\/913\/49715386\/gfac213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T06:41:57Z","timestamp":1700808117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/4\/913\/6632289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac213","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2022,7,6]]}}}